Bharat Biotech’s Covaxin Shows Promising Results in Trials

Bharat Biotech's Covaxin Shows Promising Results in Trials

Hyderabad: Bharat Biotech’s Covid Vaccine or Covaxin has been successful in inducing robust immune response, according to a research paper published on medRxiv.org.

The Covaxin vaccine, codenamed BBV152, is a whole-virion inactivated SARS-CoV-2 vaccine and was found to have induced a strong immune response in phase 1 clinical trial conducted on 375 candidates.

The research paper on Covaxin said, “Reactogenicity was absent in the majority of participants, with mild events. The majority of adverse events were mild and were resolved.”

It added that only one case of a severe reaction was recorded but it was found to be due to other reasons. “One serious adverse event was reported, which was found to be unrelated to vaccination,” said the white paper.

The news comes at a time when the Indian government is mulling over authorizing covid vaccines by Pfizer and Bharat Biotech for emergency use. According to the Health Ministry, there are six COVID-19 vaccine candidates in different clinical trial stages being developed by various manufacturers in India.

Bharat Biotech International Limited based in Hyderabad is collaborating with the Indian Council of Medical Research (ICMR) to develop and manufacture an indigenous Anti-COVID vaccine. Bharat Biotech has roped in experts from ICMR, All India Institute of Medical Sciences in Delhi and Patna.

--

--

Digital and Mobile platform for discovering and sharing news on the go

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
India Ahead News

Digital and Mobile platform for discovering and sharing news on the go